Sehui Kim

List of Publications by Year
in descending order

29	2,018	430874 18	501196 28
papers	citations	h-index	g-index

29	29	29	4606
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. Journal of Clinical Oncology, 2017, 35, 3065-3074.	1.6	349
2	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. Clinical Cancer Research, 2016, 22, 2261-2270.	7.0	217
3	Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer, 2015, 88, 24-33.	2.0	187
4	Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. European Journal of Cancer, 2015, 51, 2698-2707.	2.8	150
5	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology, 2016, 68, 1079-1089.	2.9	135
6	PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Human Pathology, 2016, 58, 7-14.	2.0	135
7	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget, 2016, 7, 15901-15914.	1.8	125
8	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1Î± and STAT3. OncoImmunology, 2016, 5, e1108514.	4.6	124
9	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. European Journal of Cancer, 2017, 75, 141-149.	2.8	84
10	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 97920-97927.	1.8	69
11	Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma. Oncotarget, 2017, 8, 13762-13769.	1.8	68
12	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. BMC Cancer, 2019, 19, 19.	2.6	66
13	Overexpression of endoplasmic reticulum stress-related proteins, XBP1s and GRP78, predicts poor prognosis in pulmonary adenocarcinoma. Lung Cancer, 2018, 122, 131-137.	2.0	44
14	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. BMC Cancer, 2016, 16, 363.	2.6	37
15	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. Scientific Reports, 2019, 9, 7680.	3.3	36
16	Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system. OncoImmunology, 2018, 7, e1442164.	4.6	34
17	MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. Lung Cancer, 2017, 106, 131-137.	2.0	30
18	High tumoral PD-L1 expression and low PD-1⁺ or CD8⁺ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. OncoImmunology, 2019, 8, e1626653.	4.6	30

#	Article	IF	Citations
19	Type 17 immunity promotes the exhaustion of CD8⁺ T cells in cancer. , 2021, 9, e002603.		20
20	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2016, 142, 873-883.	2.5	17
21	An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. Leukemia and Lymphoma, 2016, 57, 1956-1960.	1.3	15
22	Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 131-142.	2.8	14
23	Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort. Cancers, 2020, 12, 3305.	3.7	9
24	Primary Peripheral Gamma Delta T-Cell Lymphoma of the Central Nervous System: Report of a Case Involving the Intramedullary Spinal Cord and Presenting with Myelopathy. Journal of Pathology and Translational Medicine, 2019, 53, 57-61.	1.1	6
25	Utility of PDâ€L1 immunocytochemistry using bodyâ€fluid cell blocks in patients with nonâ€smallâ€cell lung cancer. Diagnostic Cytopathology, 2020, 48, 291-299.	1.0	5
26	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. Cancer Immunology, Immunotherapy, 2021, 70, 1755-1769.	4.2	4
27	Aberrant expression of napsin A in a subset of malignant lymphomas. Histology and Histopathology, 2016, 31, 213-21.	0.7	3
28	An unusual case of microsatellite instabilityâ€“high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing. Journal of Pathology and Translational Medicine, 2022, 56, 92-96.	1.1	3
29	Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma. Cancers, 2020, 12, 1669.	3.7	2